Skip to main content

Quotient to expand Alnwick

Quotient Sciences is to invest £6.3 million to expand drug substance manufacturing at the site in Alnwick, UK, which it acquired along with Arcinova in February. This will also create 80 new jobs over the next three years and boost its capacity to develop complex medicines tenfold.

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Subscribe to drug substance